Where McKay focused on the greed that caused the economic collapse in The Big Short, Bad Blood casts a critical eye on how innovative companies gain astronomical valuations, and sometimes prove too good to be true. Theranos is the blood-testing startup that Holmes founded in 2003, with claims it could test blood with only a pinprick instead of the traditional method of drawing blood by injection. That potential left Theranos with a $9 billion valuation as recently as two years ago. The company since has come under investigation over claims of inaccurate testing, and Holmes’ own worth — at one point valued at $ billion for her 50% stake — has fallen to a fraction of that. The last valuation by Forbes placed the company’s net worth at $800 million.